Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Taylor (Dunedin, New Zealand). Monitoring asthma and adjusting the inhaled steroid dose: is there a better way?. Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management

Member's Comments

No comment yet.

Related content which might interest you: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma Source: Annual Congress 2006 - Scientific year in review Year: 2006 Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma Source: Eur Respir J 2009; 34: 1052-1059 Year: 2009 Diagnosing asthma and prognostic significance of eNO Source: Annual Congress 2005 - Are we ready for "inflammometry"? The role of eNO in asthma management Year: 2005 Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship Source: Eur Respir J 2002; 20: 601-608 Year: 2002 A study of exhaled NO (FENO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 What is in the air of a child with lung disease? Source: Annual Congress 2005 - Paediatric year in review Year: 2005 Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006 Exhaled NO but not eosinophilic inflammation is reduced by inhaled corticosteroid treatment in COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016 Montelukast as add-on therapy to β-agonists and late airway response Source: Eur Respir J 2007; 30: 56-61 Year: 2007 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice? Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019 Year: 2019 Inhaled corticosteroids and β2-agonists reduces imbalance in the cellular redox status in patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 508s Year: 2004 Inhaled corticosteroids and growth of airway function in asthmatic children Source: Eur Respir J 2004; 23: 861-868 Year: 2004 Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002 Clinical utility of measuring FeNO to assess inhaled corticosteroid response in asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008